Correlation of urinary microRNA-326 with the prognosis of bladder cancer patients treated with radical cystectomy

doi:10.3877/cma.j.issn.1674-3253.2024.04.014

Abstract

Abstract:

Objective

To investigate the correlation between microRNA-326 (miR-326) in urine and the prognosis of bladder cancer patients treated with radical cystectomy.

Methods

138 patients with bladder cancer treated with radical cystectomy at Mianzhu People's Hospital, Deyang Hospital of Traditional Chinese and Western Medicine, Mianzhu City Chinese Medicine Hospital, the Third Hospital of Mianyang, Neijiang Central District People's Hospital, the Sixth People's Hospital of Deyang City, from January 2017 to February 2019 were selected as study subjects, followed up for 6 to 60 months, and divided into survival (n=95) and death (n=43) groups according to their survival status. Real-time fluorescence quantitative PCR was used to detect miR-326 levels in urine. Receiver operating characteristic (ROC) curve was used to evaluate the value of miR-326 in determining the prognosis of bladder cancer patients. Kaplan-Meier and log-rank were used to compare the survival of patients with different miR-326 level, and Cox regression was used to analyse the risk factors for the prognosis of bladder cancer patients.

Results

Age, proportion of T₄ stage and proportion of lymph node metastases were lower in the survival group than in the death group (all P<0.05). Postoperative miR-326 levels were higher in both groups than preoperatively (all P<0.05). Preoperative miR-326 level was higher in the survival group than in the death group, and the miR-326 change value was lower than in the death group (all P<0.05). The area under the ROC curve for pre-operative miR-326 to determine the prognosis of bladder cancer patients was higher than the miR-326 change value (P<0.05). Patients with preoperative miR-326≤0.40 had a lower survival rate than patients with preoperative miR-326>0.40 (P<0.05). Cox regression analysis showed that age and T-stage were independent risk factors for bladder cancer prognosis, and preoperative miR-326 was an independent protective factor for bladder cancer prognosis (all P<0.05).

Conclusion

High miR-326 levels before radical cystectomy suggest a low risk of poor prognosis in patients with bladder cancer.

Key words: Bladder cancer, Radical cystectomy, Urine, MicroRNA-326, Biomarker, PCAT6, Prognosis

Zhongwen Liu, Chang Liu, Yang Gao, Dong Liu, Shiqing Lin, Jianhua Yang, Fuyi Zhao. Correlation of urinary microRNA-326 with the prognosis of bladder cancer patients treated with radical cystectomy[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 386-391.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2024.04.014

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2024/V18/I04/386

Figures/Tables 6

References 25

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]	中国肿瘤医院泌尿肿瘤协作组. 中国膀胱癌保膀胱治疗多学科诊治协作共识[J]. 中华肿瘤杂志, 2022, 44(3): 209-218.
[3]	Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324(19): 1980-1991.
[4]	Parizi PK, Yarahmadi F, Tabar HM, et al. MicroRNAs and target molecules in bladder cancer[J]. Med Oncol, 2020, 37(12): 118.
[5]	Wei B, Wang Z, Lian Q, et al. hsa_circ_0139402 promotes bladder cancer progression by regulating hsa-miR-326/PAX8 signaling[J]. Dis Markers, 2022, 2022: 9899548.
[6]	刘振华,李向东,刘泽赋,等. 单中心1041例膀胱癌根治尿流改道患者手术疗效和并发症[J]. 中山大学学报（医学科学版）, 2022, 43(5): 818-827.
[7]	曹振学, 郭园园, 刘贝贝, 等. MiR-15a与临床膀胱癌患者术后复发的相关性分析[J]. 中华全科医学, 2021, 19(4): 547-549, 647.
[8]	Tang Q, Chen Z, Zhao L, et al. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1[J]. Aging, 2019, 11(22): 9982-9999.
[9]	Nie FR, Li QX, Wei HF, et al. MiR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4[J]. Neoplasma, 2020, 67(3): 604-613.
[10]	Moya L, Meijer J, Schubert S, et al. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis[J]. Int J Mol Sci, 2019, 20(5): 1154.
[11]	Bao Z, Gao S, Tang Q, et al. A novel role of miR-326 in colorectal carcinoma by regulating E2F1 expression[J]. J BUON, 2021, 26(2): 528-535.
[12]	Zhang Y, Chen L, Luo G. Long non-coding RNA PCAT6 regulates bladder cancer progression via the microRNA-143-3p/PDIA6 axis[J]. Exp Ther Med, 2021, 22(3): 947.
[13]	Xia W, Chen C, Zhang MR, et al. LncRNA PCAT6 aggravates the progression of bladder cancer cells by targeting miR-513a-5p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(19): 9908-9914.
[14]	Zhang D, Du D, Yi S, et al. LncRNA PCAT6: a potential biomarker for diagnosis and prognosis of bladder cancer[J]. Ann Diagn Pathol, 2020, 49: 151642.
[15]	Luo J, Zheng J, Hao W, et al. LncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR-326/hnRNPA2B1 axis in liver cancer[J]. Oncol Lett, 2021, 21(6): 471.
[16]	Liu B, Jiang H Y, Yuan T, et al. Enzalutamide-induced upregulation of PCAT6 promotes prostate cancer neuroendocrine differentiation by regulating miR-326/HNRNPA2B1 axis[J]. Front Oncol, 2021, 11: 650054.
[17]	Tu J, Wu F, Chen L, et al. Long non-coding RNA PCAT6 induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway[J]. Front Oncol, 2020, 10: 605877.
[18]	Zhu Q, Wang S, Shi Y. LncRNA PCAT6 activated by SP1 facilitates the progression of breast cancer by the miR-326/LRRC8E axis[J]. Anticancer Drugs, 2022, 33(2): 178-190.
[19]	Lai C, Wu Z, Shi J, et al. Autophagy-related long noncoding RNAs can predict prognosis in patients with bladder cancer[J]. Aging, 2020, 12(21): 21582-21596.
[20]	王逸秋, 沈文浩, 张瑞赟, 等. 前白蛋白水平对行根治性膀胱切除术的膀胱癌患者预后的预测价值[J]. 上海医学, 2021, 44(7): 496-500.
[21]	周佳维, 汪雄, 沈德贇, 等. 中性粒淋巴细胞比值与血小板淋巴细胞比值对腹腔镜膀胱癌根治术后肌层浸润性膀胱癌患者预后的预测价值[J]. 临床泌尿外科杂志, 2022, 37(2): 104-108.
[22]	杜光辉, 付志刚, 薛敏敏. 膀胱癌发病危险因素及与PET-CT辐射的相关性[J]. 实用癌症杂志, 2021, 36(11): 1904-1908.
[23]	符海能, 梁培育, 王声兴, 等. 术前临床实验室指标对肌层浸润性膀胱癌根治术后疗效及预后的影响[J]. 国际检验医学杂志, 2023, 44(10): 1167-1171.
[24]	裴德龙, 颜凯, 龚卓, 等. 不同尿流改道方式对46例老年膀胱癌患者手术并发症的影响[J]. 延边大学医学学报, 2021, 44(4): 269-273.
[25]	斯热努尔·艾合买提, 张瑞丽, 魏媛, 等. 肌层浸润性膀胱癌患者根治术后预后相关因素分析[J]. 现代肿瘤医学, 2020, 28(17): 2995-2999.

项目	生存组（n=95）	死亡组（n=43）	统计值	P值
年龄[岁，(±s)]	58±5	61±6	t=3.022	0.003
性别[例(%)]			χ²=1.081	0.298
男性	78(82.11)	32(74.42)
女性	17(17.89)	11(25.58)
吸烟史[例(%)]			χ²=0.243	0.622
有	27(28.42)	14(32.56)
无	68(71.58)	29(67.44)
T分期[例(%)]			χ²=14.207	0.001
T₂	44(46.32)	8(18.60)
T₃	43(45.26)	23(53.49)
T₄	8(8.42)	12(27.91)
淋巴结转移[例(%)]			χ²=16.922	<0.001
有	12(12.63)	19(44.19)
无	83(87.37)	24(55.81)
肿瘤大小[例(%)]			χ²=0.003	0.959
≤3 cm	57(60.00)	26(60.47)
> 3 cm	38(40.00)	17(39.53)
肿瘤数目[例(%)]			χ²=0.008	0.927
单发	70(73.68)	32(74.42)
多发	25(26.32)	11(25.58)
尿道改流方式[例(%)]			χ²=0.375	0.825
通道式的非可控式尿流改道	32(33.69)	16(37.21)
通道式的非可控式尿流改道	32(33.69)	13(30.23)
输尿管皮肤改道	31(32.62)	14(32.56)

项目	生存组（n=95）	死亡组（n=43）	统计值	P值
年龄[岁，(±s)]	58±5	61±6	t=3.022	0.003
性别[例(%)]			χ²=1.081	0.298
男性	78(82.11)	32(74.42)
女性	17(17.89)	11(25.58)
吸烟史[例(%)]			χ²=0.243	0.622
有	27(28.42)	14(32.56)
无	68(71.58)	29(67.44)
T分期[例(%)]			χ²=14.207	0.001
T₂	44(46.32)	8(18.60)
T₃	43(45.26)	23(53.49)
T₄	8(8.42)	12(27.91)
淋巴结转移[例(%)]			χ²=16.922	<0.001
有	12(12.63)	19(44.19)
无	83(87.37)	24(55.81)
肿瘤大小[例(%)]			χ²=0.003	0.959
≤3 cm	57(60.00)	26(60.47)
> 3 cm	38(40.00)	17(39.53)
肿瘤数目[例(%)]			χ²=0.008	0.927
单发	70(73.68)	32(74.42)
多发	25(26.32)	11(25.58)
尿道改流方式[例(%)]			χ²=0.375	0.825
通道式的非可控式尿流改道	32(33.69)	16(37.21)
通道式的非可控式尿流改道	32(33.69)	13(30.23)
输尿管皮肤改道	31(32.62)	14(32.56)

组别	倾向性评分匹配前				1∶1倾向性评分匹配
组别	例数	术前	术后	变化值	例数	术前	术后	变化值
生存组	95	0.48±0.05	0.73±0.13	0.26（0.16，0.33）	18	0.49±0.05	0.76±0.12	0.27±0.12
死亡组	43	0.37±0.08	0.73±0.11	0.36（0.27，0.45）	18	0.39±0.09	0.76±0.09	0.37±0.10
统计值		t=8.041	t=0.176	Z=3.816		t=4.365	t=0.048	t=3.725
P值		<0.001	0.861	<0.001		<0.001	0.962	0.010

组别	倾向性评分匹配前				1∶1倾向性评分匹配
组别	例数	术前	术后	变化值	例数	术前	术后	变化值
生存组	95	0.48±0.05	0.73±0.13	0.26（0.16，0.33）	18	0.49±0.05	0.76±0.12	0.27±0.12
死亡组	43	0.37±0.08	0.73±0.11	0.36（0.27，0.45）	18	0.39±0.09	0.76±0.09	0.37±0.10
统计值		t=8.041	t=0.176	Z=3.816		t=4.365	t=0.048	t=3.725
P值		<0.001	0.861	<0.001		<0.001	0.962	0.010

因素	赋值
年龄	原始值
性别	女性=0，男性=1
吸烟史	无=0，有=1
T分期	T₂=0，T₃=1，T₄=2
淋巴结转移	无=0，有=1
肿瘤大小	≤3 cm=0，>3 cm=1
肿瘤数目	单发=0，多发=1
术前miR-326	≤0.40=0，>0.4=1

Please choose a citation manager

Content to export